The molecular biology of lung cancer

Our plain-English summary of The molecular biology of lung cancer, by J.A. Ross, G.D. Rosen (Current Opinion in Pulmonary Medicine, 2002).

The study

• Authors: J.A. Ross, G.D. Rosen
• Journal: Current Opinion in Pulmonary Medicine
• Published: 2002;8(4):265-9
• Type of article: Review
• Cited by: 9 articles, as counted by NIH iCite
• Read it: PubMed · Publisher

Abstract

Lung cancer is the result of molecular changes that occur in the cell, resulting in the deregulation of pathways which control normal cellular growth, differentiation, and apoptosis. Several of these pathways contain well-characterized proto-oncogenes and tumor suppressor genes which are found to be mutated or have abnormal expression patterns in lung cancer. The molecular changes that characterize lung cancer are complex, but it is known that cigarette smoking causes most squamous cell and small-cell carcinomas. However, the association between cigarette smoke and adenocarcinoma is less clear. Environmental factors, such as air pollutants, radon, and asbestos, likely contribute to the development of lung cancer. In this review, we discuss the major molecular abnormalities in lung cancer with a review of recent studies that begin to decipher the role that different tumor suppressor genes and oncogenes play in the pathogenesis of lung cancer. Also, we highlight the research that has identified new genes which may play a role in lung cancer pathogenesis or progression.

In plain English

This article was a review of research on the molecular biology of lung cancer. It did not study asbestos. Asbestos was mentioned once, in the opening summary, where the authors wrote that environmental factors such as air pollutants, radon and asbestos likely contribute to lung cancer. Citing other studies, the review reported K-ras gene mutations in approximately 50% of non-small-cell lung cancers (NSCLC). It reported Rb gene mutations in virtually all small-cell lung cancers (SCLC) and approximately 35% of NSCLC, and p53 gene mutations in 50% of NSCLC and 70% of SCLC. It described a mouse study in which 100% of mice carrying a K-ras gene that could switch on by spontaneous mutation developed lung adenocarcinomas. The authors also described their own unpublished analysis (a manuscript in preparation) of approximately 80 lung cancer samples, in which expression of the ING1 gene was reduced in most tumor samples compared with normal lung tissue. The authors concluded that the events that start lung cancer are largely unknown. They expressed hope that large-scale gene expression analysis may help early detection and tumor classification.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Narrative review of published research on the molecular biology of lung cancer
• Who was studied: No study population. This was a review of published laboratory, animal and human tumor studies on lung cancer genes. It also briefly described the authors' own unpublished analysis of approximately 80 human primary and metastatic lung cancer samples.
• Exposure: Asbestos was not studied. It was mentioned only once, alongside air pollutants and radon, as an environmental factor the authors said likely contributes to lung cancer. The review itself was about gene changes in lung cancer cells, not exposures.
• Main results:
  • Citing other studies, the review reported K-ras mutations in approximately 50% of non-small-cell lung cancers (NSCLC), while K-ras function is maintained in most small-cell lung cancers (SCLC).
  • Citing a mouse study, the review reported that in mice carrying a K-ras gene that could be activated by spontaneous mutation, 100% of mice developed lung adenocarcinomas and 38% developed thymic lymphoma.
  • Citing other studies, the review reported that the Rb gene is mutated in virtually all SCLC tumors and approximately 35% of NSCLC.
  • Citing other work, the review reported p53 gene mutation in 50% of non-small-cell lung cancers and 70% of SCLC.
  • In the authors' own unpublished microarray analysis (a manuscript in preparation) of approximately 80 lung cancer samples, ING1 expression was reduced in most tumor samples compared with normal lung tissue. It was reduced at least 4-fold in all metastatic tumors compared with the matched primary tumor.
  • Citing two gene expression array studies, the review reported that no single gene or group of genes was consistently raised or lowered in a particular type of lung cancer.
• The authors' conclusion: The authors concluded that several molecular events contribute to lung cancer and that the events that start it are largely unknown. They hoped that large-scale gene expression analysis may help improve early detection and classification of lung tumors.

Topics

The National Library of Medicine indexes this study under subjects our site covers: Lung cancer.

Medical terms in this study, explained in our Lexicon: Lung Cancer, Apoptosis, Tumor Suppressor Gene, Squamous Cell, Carcinoma, Adenocarcinoma.

Related studies

• Progressive multifocal leukoencephalopathy: molecular biology, pathogenesis and clinical impact — T. Weber, E.O. Major (1997)
• Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma — K. Kaira, M. Serizawa, et al. (2012)
• Molecular biology of malignant mesothelioma — Y. Sekido (2008)
• Splicing molecular biology and novel therapies in diffuse malignant peritoneal mesothelioma — A. Napolitano (2019)
• Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan — J.A. Gibson, K.E. Finberg, et al. (2021)
• Distinct DNA methylation profiles in malignant mesothelioma, lung adenocarcinoma, and non-tumor lung — J.A. Tsou, L.Y. Shen, et al. (2005)

Browse more research in Current Opinion in Pulmonary Medicine, or return to medical research.